Given the NF-κB function approach as well as its relation to osteoporosis and breast cancer, it is obvious why the recognition of the NF-κB activity in the crossway between RANK/RANKL and SPRMs is crucial to provide the evidence of useful SPRMs as an anti-RANKL and antiproliferative agents into osteoporosis and breast cancer treatment. The gene discussed is TNFSF11; the disease is breast carcinoma.